CA2927321A1 — Formulations and methods for increasing or reducing mucus
Assigned to ForSight Vision5 Inc · Expires 2015-04-23 · 11y expired
What this patent protects
The present disclosure is directed to a pharmaceutical delivery device useful for the treatment of ocular diseases and disorders through sustained release of therapeutic doses of a pharmaceutical agent, while increasing or reducing formation and/or accumulation of mucus.
USPTO Abstract
The present disclosure is directed to a pharmaceutical delivery device useful for the treatment of ocular diseases and disorders through sustained release of therapeutic doses of a pharmaceutical agent, while increasing or reducing formation and/or accumulation of mucus.
Drugs covered by this patent
- Sandimmune (cyclosporine) · Novartis AG (originally Sandoz)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.